Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript


Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Conference Call April 1, 2024 4:30 PM ET

Company Participants

Alex Arrow – CFO
Garo Armen – Executive Chairman
Andrew Slee – COO
Bob Stein – CMO

Conference Call Participants

William Wood – B. Riley Securities

Operator

Greetings. Welcome to the Protagenic Therapeutics’ Fourth Quarter and Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.

I will now turn the conference over to your host, Alex Arrow. You may begin.

Alex Arrow

Thank you very much. Good afternoon everyone. I’d like to welcome you to Protagenic Therapeutics’ earnings call to review our fourth quarter and fiscal year 2023 year-end operating results.

Participating on the call today with me is our Executive Chairman, Dr. Garo Armen; our Chief Operating Officer, Dr. Andrew Slee; and our Chief Medical Officer, Dr. Bob Stein. I’d like to thank them and each one of you for your time and commitment to Protagenic Therapeutics. I’m the company’s Chief Financial Officer, Alexandre Arrow.

2023 was a pivotal year in the history of our company. During 2023, we began our first-ever clinical trial of our lead product known as PT00114, a drug candidate that has the potential to benefit millions of patients suffering from depression, chronic anxiety, PTSD, or drug addiction. On today’s call, we’ll be providing a detailed discussion about the significance of this clinical trial and an outlook for what to expect specifically in 2024.

Before we begin those remarks, I’d like to note that the following commentary will include some forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from those that we forecast.

Forward-looking statements include

[colabot6]

Leave a Comment

Your email address will not be published. Required fields are marked *